This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the
safety and efficacy of emricasan in improving event-free survival based on a composite
clinical endpoint (where all-cause mortality, new decompensation events, and MELD score
progression are events) in subjects with decompensated NASH cirrhosis.

The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve
cognitive function by having less effect on brain blood flow.

The primary purpose of this project is to determine if acute monitoring of shunt patency via
ultrasound elastography measurements of splenic stiffness before and after TIPS placement
results in reduced morbidity and mortality from shunt failure.

The primary objectives of this study are to evaluate the effect of Obeticholic Acid
treatment compared to placebo on 1) histological improvement and 2) liver-related clinical
outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver

The ALF-MBT protocol is for a multicenter, open label, non-randomized study to determine the
value of Breath Identification® (BreathID®) Acute Liver Failure 13C-Methacetin Breath Test
System in predicting the outcome of patients diagnosed with acute liver failure who meet
inclusion/exclusion criteria.

Up to 200 evaluable patients will be enrolled. An evaluable patient is one who has completed
one or more breath tests for at least 30 minutes after administration of the 13C-Methacetin
solution (test substrate).

The Breath Test will be performed on all patients upon admission into the study (Day 1) and
repeated on Days 2, 3, 5 and 7 provided no contra-indications are present. Each test
continuously measures changes in the metabolism of the 13C-Methacetin in order to assess the
improvement or deterioration in liver metabolic function about improvement or deterioration
in liver metabolic function.

Patients will be contacted for the Day 21 follow up (21 days after enrollment into the
trial) to determine spontaneous survival, transplantation and occurrence of serious adverse
events since the patient's last study treatment.